InvestSMART

Innate Immunotherapeutics Limited (ASX: IIL) - Announcements

Current share price for IIL : $0.360 0.02 (5.88%)+

ASX company news and announcements for Innate Immunotherapeutics Limited (IIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Innate Immunotherapeutics Limited (IIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Innate Immunotherapeutics Limited (IIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Innate Immunotherapeutics Limited (IIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Amplia Investor Introduction 5 Sep 2018 2:52PM $0.360 $0.360 fallen by 0%
- Change of Name to Amplia Therapeutics Limited - ATX 5 Sep 2018 1:44PM $0.360 $0.360 fallen by 0%
- Change of Director's Interest - Cooke - Options 4 Sep 2018 3:38PM $0.340 $0.360 risen by 5.88%
- Change of Director's Interest - Peach - Options 4 Sep 2018 3:36PM $0.340 $0.360 risen by 5.88%
- Change of Director's Interest - Wilkinson - Options 4 Sep 2018 3:34PM $0.340 $0.360 risen by 5.88%
- Appendix 3B - Options 4 Sep 2018 2:15PM $0.340 $0.360 risen by 5.88%
- Results of Annual General Meeting 30 Aug 2018 11:30AM $0.370 $0.360 fallen by 2.70%
- Annual General Meeting Venue 28 Aug 2018 3:11PM $0.335 $0.360 risen by 7.46%
- Response to ASX Query 14 Aug 2018 11:03AM $0.340 $0.360 risen by 5.88%
- US Media Coverage - Mr Chris Collins 9 Aug 2018 10:11AM $0.295 $0.360 risen by 22.03%
- Innate-Amplia Investor Introduction 7 Aug 2018 8:22AM $0.300 $0.360 risen by 20%
- Appendix 4C - June 2018 Quarter Cashflow Statement 30 Jul 2018 9:52AM $0.300 $0.360 risen by 20%
- Appendix 4G - Key to Corporate Governance Disclosures 26 Jul 2018 1:24PM $0.310 $0.360 risen by 16.13%
- Corporate Governance Statement 26 Jul 2018 1:23PM $0.310 $0.360 risen by 16.13%
- Annual Report to shareholders - YE 31 March 2018 26 Jul 2018 1:23PM $0.310 $0.360 risen by 16.13%
- Notice of Annual General Meeting/Proxy Form 26 Jul 2018 1:19PM $0.310 $0.360 risen by 16.13%
- European Patent Granted for Innate's Drug Candidate AMP-886 23 Jul 2018 8:37AM $0.300 $0.360 risen by 20%
- Full Year Statutory Accounts - Year Ended 31 March 2018 20 Jun 2018 5:27PM $0.400 $0.360 fallen by 10%
- Change of Director's Interest Notice - Andrew Cooke 18 Jun 2018 8:20AM $0.395 $0.360 fallen by 8.86%
- Preliminary Final Report - Year Ended 31 March 2018 31 May 2018 8:25AM $0.405 $0.360 fallen by 11.11%
- Dr. Warwick Tong appointed as Chairman 28 May 2018 12:11PM $0.440 $0.360 fallen by 18.18%
- Notice of Initial Substantial Holder CTxCRC Ltd and CTxT P/L 28 May 2018 10:03AM $0.420 $0.360 fallen by 14.29%
- Change of Registered Office and Principal Place of Business 28 May 2018 10:02AM $0.420 $0.360 fallen by 14.29%
- Becoming a substantial holder - M and T Devlin 34th Avenue 14 May 2018 11:07AM $0.440 $0.360 fallen by 18.18%
- Becoming a Substantial Holder - Christian Behrenbruch 11 May 2018 3:24PM $0.390 $0.360 fallen by 7.69%

1 - 25 of 191 results

Page 1 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.